We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sanofi has extended its master services agreement with Swedish drug discovery firm Beactica to characterise the interactions between new therapeutics and their target proteins.